Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05953688 · ClinicalTrials.gov registry record · Phase 2
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
A Phase 2 study, sponsored by Alumis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT05953688 is a Phase 2 study that was terminated before completion, run by Alumis. The registered enrollment target is 36 participants.
The verdict
NCT05953688, a Phase 2 study, was terminated before completion, sponsored by Alumis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.
Interventions
- DRUG ESK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2024-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05953688
The ClinicalTrials.gov registry entry for NCT05953688 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ESK-001 is the first listed.
NCT05953688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05953688 about?
NCT05953688 is a clinical study titled "POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU". This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.
What is the current status of trial NCT05953688?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-06-14. Estimated completion is 2024-08-13.
What interventions are being tested in trial NCT05953688?
The interventions under investigation include: ESK-001 (DRUG).
Who is sponsoring clinical trial NCT05953688?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.